Trial reportActa tropica2025
Defining Aedes aegypti density thresholds for preventing human arboviral infections.
Trial report in Acta tropica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Strategies for controllingCaribbean journal of science · 2026Article
- Investigation of and Response to Autochthonous Dengue, Los Angeles County, California, USA, August-November 2024.Emerging infectious diseases · 2026Article
- Evaluation of Effectiveness of Autocidal Gravid Ovitraps for Preventing Zika Virus Infection, Puerto Rico, USA.Emerging infectious diseases · 2026Article
- Monitoring Dengue Virus inViruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Effective control of local dengue virus transmission requires reducing the population of mosquitoes below a critical density threshold. Aedes aegypti density thresholds can serve as targets for intervention effectiveness. Most thresholds have been identified by correlating vector densities with pathogen transmission events. However, despite previous descriptive research there is a need for rigorously controlled field studies to clarify the interactions between Ae. aegypti density and human infections. We report on a multi-arm cluster randomized field trial aimed at determining the number of female Ae. aegypti mosquitoes below which dengue outbreaks are limited. We implemented four mosquito control treatments in a dose-response trial, using zero to three Autocidal Gravid Ovitraps (AGO traps) per house across study neighborhoods in Caguas, Puerto Rico from January 2021 to June 2024. We anticipated that significant reductions in Ae. aegypti populations would indicate a threshold density if low or no prevalence of dengue viruses was observed in mosquitoes or antibodies in residents through IgM and IgG serological testing. Results showed that female Ae. aegypti densities decreased by 44 %, 60 %, and 80 % in clusters with one, two, and three traps/house, respectively. The expected number of dengue-infected mosquitoes per thousand were 2.01, 1.70, 0.60, and 0.36 in clusters with zero, one, two, and three traps/house, respectively. Increases in dengue IgG antibody prevalence from 2022 to 2023 were noted only among residents aged 1-10 years, with rates of 25 %, 18 %, 6 %, and 5.9 % corresponding to the number of traps used. To reduce dengue incidence, local populations of Ae. aegypti should be kept below 4 females per AGO trap per week.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.